Silexion Therapeutics (SLXN) Competitors $7.36 -0.04 (-0.54%) Closing price 08/14/2025 04:00 PM EasternExtended Trading$7.28 -0.08 (-1.09%) As of 08/14/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock SLXN vs. CVKD, BCAB, EQ, ATNF, FNCH, RLMD, BTAI, CMMB, NRSN, and ABPShould you be buying Silexion Therapeutics stock or one of its competitors? The main competitors of Silexion Therapeutics include Cadrenal Therapeutics (CVKD), BioAtla (BCAB), Equillium (EQ), 180 Life Sciences (ATNF), Finch Therapeutics Group (FNCH), Relmada Therapeutics (RLMD), BioXcel Therapeutics (BTAI), Chemomab Therapeutics (CMMB), NeuroSense Therapeutics (NRSN), and Abpro (ABP). These companies are all part of the "pharmaceutical products" industry. Silexion Therapeutics vs. Its Competitors Cadrenal Therapeutics BioAtla Equillium 180 Life Sciences Finch Therapeutics Group Relmada Therapeutics BioXcel Therapeutics Chemomab Therapeutics NeuroSense Therapeutics Abpro Silexion Therapeutics (NASDAQ:SLXN) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends. Which has more risk & volatility, SLXN or CVKD? Silexion Therapeutics has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Comparatively, Cadrenal Therapeutics has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Is SLXN or CVKD more profitable? Silexion Therapeutics' return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Silexion TherapeuticsN/A N/A -355.74% Cadrenal Therapeutics N/A -265.37%-196.38% Do analysts rate SLXN or CVKD? Silexion Therapeutics currently has a consensus price target of $75.00, indicating a potential upside of 919.02%. Cadrenal Therapeutics has a consensus price target of $32.00, indicating a potential upside of 147.68%. Given Silexion Therapeutics' higher probable upside, equities research analysts plainly believe Silexion Therapeutics is more favorable than Cadrenal Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Silexion Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Cadrenal Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals have more ownership in SLXN or CVKD? 11.0% of Silexion Therapeutics shares are owned by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are owned by institutional investors. 6.0% of Silexion Therapeutics shares are owned by insiders. Comparatively, 26.1% of Cadrenal Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media prefer SLXN or CVKD? In the previous week, Cadrenal Therapeutics had 4 more articles in the media than Silexion Therapeutics. MarketBeat recorded 9 mentions for Cadrenal Therapeutics and 5 mentions for Silexion Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.32 beat Silexion Therapeutics' score of 0.18 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Silexion Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cadrenal Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has higher earnings and valuation, SLXN or CVKD? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSilexion TherapeuticsN/AN/A-$16.44MN/AN/ACadrenal TherapeuticsN/AN/A-$10.65M-$8.88-1.45 SummaryCadrenal Therapeutics beats Silexion Therapeutics on 6 of the 9 factors compared between the two stocks. Get Silexion Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SLXN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SLXN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SLXN vs. The Competition Export to ExcelMetricSilexion TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.29M$3.10B$5.61B$9.84BDividend YieldN/A2.23%4.61%4.07%P/E RatioN/A20.4930.2825.74Price / SalesN/A356.37460.47115.79Price / CashN/A43.0338.2159.48Price / Book35.058.608.856.15Net Income-$16.44M-$54.65M$3.25B$265.06M7 Day Performance-10.57%5.86%3.72%2.60%1 Month Performance-35.45%8.86%5.86%2.83%1 Year PerformanceN/A13.33%30.34%25.58% Silexion Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SLXNSilexion Therapeutics1.6397 of 5 stars$7.36-0.5%$75.00+919.0%N/A$4.29MN/A0.00N/AEarnings ReportGap DownCVKDCadrenal Therapeutics2.9055 of 5 stars$10.40+18.0%$32.00+207.7%N/A$20.46MN/A-1.124Earnings ReportShort Interest ↑Analyst RevisionGap UpBCABBioAtla2.2877 of 5 stars$0.35+4.4%$5.00+1,345.1%-78.3%$20.21M$11M-0.2860News CoverageAnalyst DowngradeAnalyst RevisionEQEquillium3.0484 of 5 stars$0.57+0.7%$3.00+429.1%+22.7%$20.15M$41.10M-1.4540Earnings ReportShort Interest ↓Gap UpATNF180 Life Sciences0.5078 of 5 stars$3.31+3.9%N/A+312.0%$19.98MN/A-0.227News CoverageAnalyst ForecastShort Interest ↑Gap DownHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$12.29-1.4%N/A+18.8%$19.74MN/A-1.39190RLMDRelmada Therapeutics4.5794 of 5 stars$0.58-5.0%$5.00+756.2%-76.4%$19.25MN/A-0.2310BTAIBioXcel Therapeutics4.4611 of 5 stars$3.08+21.1%$42.60+1,284.9%-56.3%$18.70M$2.27M-0.2390Earnings ReportShort Interest ↓Gap DownHigh Trading VolumeCMMBChemomab Therapeutics3.6576 of 5 stars$0.99-1.0%$8.50+758.6%-14.5%$18.67MN/A-1.3020News CoverageEarnings ReportUpcoming EarningsShort Interest ↓NRSNNeuroSense Therapeutics2.4005 of 5 stars$1.35+7.2%$14.00+936.3%+67.1%$18.45MN/A-2.5010Short Interest ↑ABPAbproN/A$0.30+26.4%$4.00+1,223.2%N/A$18.38M$180K0.0015Positive NewsEarnings ReportGap DownHigh Trading Volume Related Companies and Tools Related Companies Cadrenal Therapeutics Alternatives BioAtla Alternatives Equillium Alternatives 180 Life Sciences Alternatives Finch Therapeutics Group Alternatives Relmada Therapeutics Alternatives BioXcel Therapeutics Alternatives Chemomab Therapeutics Alternatives NeuroSense Therapeutics Alternatives Abpro Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SLXN) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access